Regeneron (RGO) Stock Forecast & Price Target

Compare

2 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

RGO Analyst Ratings

Strong Buy

17 Buy

3 Hold

1 Sell

Based on 21 analysts giving stock ratings to

Regeneron

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

RGO Stock 12 Month Forecast

Average Price Target

€626.24

▲(30.57% Upside)

Based on 21 Wall Street analysts offering 12 month price targets for Regeneron in the last 3 months. The average price target is €626.24 with a high forecast of €758.09 and a low forecast of €462.52. The average price target represents a 30.57% change from the last price of €479.60.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"432":"€432","1071":"€1,071","591.75":"€591.8","751.5":"€751.5","911.25":"€911.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":758.0932869,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€758.09</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":626.236162392,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€626.24</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":462.52208403,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€462.52</span>\n  </div></div>","useHTML":true}}],"tickPositions":[432,591.75,751.5,911.25,1071],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,500,519.8533297615385,539.706659523077,559.5599892846153,579.4133190461538,599.2666488076923,619.1199785692307,638.9733083307692,658.8266380923077,678.6799678538462,698.5332976153845,718.386627376923,738.2399571384615,{"y":758.0932869,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,500,509.7104740301538,519.4209480603076,529.1314220904616,538.8418961206154,548.5523701507692,558.262844180923,567.973318211077,577.6837922412308,587.3942662713846,597.1047403015384,606.8152143316923,616.5256883618462,{"y":626.236162392,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,500,497.11708338692307,494.23416677384614,491.3512501607692,488.4683335476923,485.58541693461535,482.7025003215384,479.81958370846155,476.9366670953846,474.0537504823077,471.17083386923076,468.28791725615383,465.4050006430769,{"y":462.52208403,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1070.865,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":943.317,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 57,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":778.829,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 59,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":720.083,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":673.883,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":652.575,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":670.971,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":579.647,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":494.105,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":433.434,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 65,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":441.621,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":469.279,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 60,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":500,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 57,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€758.09

Average Price Target€626.24

Lowest Price Target€462.52

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Christopher Raymond

Raymond James

€574.39

Buy

19.76%

Upside

Reiterated

09/26/25

Raymond James Remains a Buy on Regeneron (REGN)

William Pickering

Bernstein

€666.56

Buy

38.98%

Upside

Reiterated

09/26/25

Regeneron (REGN) Gets a Buy from Bernstein

John Newman

Canaccord Genuity

€725.45

Buy

51.26%

Upside

Reiterated

09/26/25

Positive Outlook on Regeneron Amidst EYLEA Challenges: Strategic Focus on GLP-1 Therapies for Alzheimer's

Mohit Bansal

Wells Fargo

€495.02

Hold

3.21%

Upside

Reiterated

09/18/25

Wells Fargo Keeps Their Hold Rating on Regeneron (REGN)

Chris Schott

J.P. Morgan

€682.78

Buy

42.36%

Upside

Reiterated

09/16/25

J.P. Morgan Reaffirms Their Buy Rating on Regeneron (REGN)

Evan Seigerman

BMO Capital

€546.22

Buy

13.89%

Upside

Reiterated

09/08/25

Buy Rating for Regeneron Amid Promising Allergy Treatment Trials and Strong Oncology Prospects

Cory Kasimov

Evercore ISI

€640.11

Buy

33.47%

Upside

Reiterated

08/27/25

Regeneron (REGN) Gets a Buy from Evercore ISI

Trung Huynh

UBS

€507.82

Hold

5.88%

Upside

Reiterated

08/27/25

UBS Reaffirms Their Hold Rating on Regeneron (REGN)

Akash Tewari

Jefferies

€693.88→€709.24

Buy

47.88%

Upside

Reiterated

08/27/25

Regeneron (REGN) Receives a Buy from Jefferies

David Risinger

Leerink Partners

―

Buy

―

Reiterated

08/26/25

Regeneron's Promising Factor XI Programs: A Potential Game-Changer in the Anticoagulation Market

Terence Flynn

Morgan Stanley

€649.49

Buy

35.42%

Upside

Reiterated

08/26/25

Analysts' Top Healthcare Picks: Regeneron (REGN), Indivior (INDV)

Tyler Van Buren

TD Cowen

€665.71

Buy

38.81%

Upside

Reiterated

08/14/25

TD Cowen Reaffirms Their Buy Rating on Regeneron (REGN)

Simon Baker CFA

Redburn Atlantic

€759.59

Buy

58.38%

Upside

Initiated

08/14/25

Regeneron (REGN) Gets a Buy from Redburn Atlantic

Carter Gould

Cantor Fitzgerald

€578.66

Buy

20.65%

Upside

Reiterated

08/13/25

Cantor Fitzgerald Reaffirms Their Buy Rating on Regeneron (REGN)

Srikripa Devarakonda

Truist Financial

€802.27→€693.02

Buy

44.50%

Upside

Reiterated

08/11/25

Truist Financial Reaffirms Their Buy Rating on Regeneron (REGN)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Christopher Raymond

Raymond James

€574.39

Buy

19.76%

Upside

Reiterated

09/26/25

Raymond James Remains a Buy on Regeneron (REGN)

William Pickering

Bernstein

€666.56

Buy

38.98%

Upside

Reiterated

09/26/25

Regeneron (REGN) Gets a Buy from Bernstein

John Newman

Canaccord Genuity

€725.45

Buy

51.26%

Upside

Reiterated

09/26/25

Positive Outlook on Regeneron Amidst EYLEA Challenges: Strategic Focus on GLP-1 Therapies for Alzheimer's

Mohit Bansal

Wells Fargo

€495.02

Hold

3.21%

Upside

Reiterated

09/18/25

Wells Fargo Keeps Their Hold Rating on Regeneron (REGN)

Chris Schott

J.P. Morgan

€682.78

Buy

42.36%

Upside

Reiterated

09/16/25

J.P. Morgan Reaffirms Their Buy Rating on Regeneron (REGN)

Evan Seigerman

BMO Capital

€546.22

Buy

13.89%

Upside

Reiterated

09/08/25

Buy Rating for Regeneron Amid Promising Allergy Treatment Trials and Strong Oncology Prospects

Cory Kasimov

Evercore ISI

€640.11

Buy

33.47%

Upside

Reiterated

08/27/25

Regeneron (REGN) Gets a Buy from Evercore ISI

Trung Huynh

UBS

€507.82

Hold

5.88%

Upside

Reiterated

08/27/25

UBS Reaffirms Their Hold Rating on Regeneron (REGN)

Akash Tewari

Jefferies

€693.88→€709.24

Buy

47.88%

Upside

Reiterated

08/27/25

Regeneron (REGN) Receives a Buy from Jefferies

David Risinger

Leerink Partners

―

Buy

―

Reiterated

08/26/25

Regeneron's Promising Factor XI Programs: A Potential Game-Changer in the Anticoagulation Market

Terence Flynn

Morgan Stanley

€649.49

Buy

35.42%

Upside

Reiterated

08/26/25

Analysts' Top Healthcare Picks: Regeneron (REGN), Indivior (INDV)

Tyler Van Buren

TD Cowen

€665.71

Buy

38.81%

Upside

Reiterated

08/14/25

TD Cowen Reaffirms Their Buy Rating on Regeneron (REGN)

Simon Baker CFA

Redburn Atlantic

€759.59

Buy

58.38%

Upside

Initiated

08/14/25

Regeneron (REGN) Gets a Buy from Redburn Atlantic

Carter Gould

Cantor Fitzgerald

€578.66

Buy

20.65%

Upside

Reiterated

08/13/25

Cantor Fitzgerald Reaffirms Their Buy Rating on Regeneron (REGN)

Srikripa Devarakonda

Truist Financial

€802.27→€693.02

Buy

44.50%

Upside

Reiterated

08/11/25

Truist Financial Reaffirms Their Buy Rating on Regeneron (REGN)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Regeneron

1 Month

xxx

Success Rate

12/19 ratings generated profit

Average Return

+0.74%

reiterated a xxx

rating 17 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 63.16% of your transactions generating a profit, with an average return of +0.74% per trade.

3 Months

xxx

Success Rate

23/39 ratings generated profit

Average Return

+2.78%

reiterated a xxx

rating 7 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 58.97% of your transactions generating a profit, with an average return of +2.78% per trade.

1 Year

David RisingerLeerink Partners

Success Rate

17/24 ratings generated profit

Average Return

+11.82%

reiterated a buy rating 3 days ago

Copying David Risinger's trades and holding each position for 1 Year would result in 70.83% of your transactions generating a profit, with an average return of +11.82% per trade.

2 Years

xxx

Success Rate

17/24 ratings generated profit

Average Return

+13.05%

reiterated a xxx

rating 3 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 70.83% of your transactions generating a profit, with an average return of +13.05% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

RGO Analyst Recommendation Trends

Rating

May 25

Jun 25

Jul 25

Aug 25

Sep 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, RGO has received 57 Buy Ratings, 8 Hold Ratings, and 2 Sell Ratings. RGO average Analyst price target in the past 3 months is 626.24.

Each month's total comprises the sum of three months' worth of ratings.

RGO Financial Forecast

RGO Earnings Forecast

Next quarter’s earnings estimate for RGO is €8.25 with a range of €6.48 to €9.63. The previous quarter’s EPS was €10.98. RGO beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year RGO has Preformed in-line its overall industry.

RGO Sales Forecast

Next quarter’s sales forecast for RGO is €3.04B with a range of €2.89B to €3.23B. The previous quarter’s sales results were €3.13B. RGO beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year RGO has Preformed in-line its overall industry.

RGO Stock Forecast FAQ

What is DE:RGO’s average 12-month price target, according to analysts?

Based on analyst ratings, Regeneron Pharmaceuticals’s 12-month average price target is 626.24.

What is DE:RGO’s upside potential, based on the analysts’ average price target?

Regeneron Pharmaceuticals has 30.57% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Regeneron Pharmaceuticals a Buy, Sell or Hold?

Regeneron Pharmaceuticals has a consensus rating of Strong Buy, which is based on 17 buy ratings, 3 hold ratings and 1 sell ratings.

What is Regeneron Pharmaceuticals’s share price target?

The average share price target for Regeneron Pharmaceuticals is 626.24. This is based on 21 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €758.09 ,and the lowest forecast is €462.52. The average share price target represents 30.57% Increase from the current price of €479.6.

What do analysts say about Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 21 Wall Streets Analysts.

How can I buy shares of Regeneron Pharmaceuticals?

To buy shares of DE:RGO, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Regeneron (RGO) Stock Forecast & Price Target

RGO Analyst Ratings

RGO Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Regeneron

RGO Analyst Recommendation Trends

RGO Financial Forecast

RGO Earnings Forecast

RGO Sales Forecast

RGO Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts